Cadence Neuroscience raises $26M to support epilepsy neuromod therapy
18 May 2023
The Angelini Lumira Biosciences Fund led the round. It also included new investors F-Prime Capital, LivaNova USA, Angelini Ventures, Spectrum Financial Services and Mayo Clinic. Series A lead investor, Jazz Venture Partners, also contributed.
In connection with the financing, Gerry Brunk of Lumira and Kevin Chu of F-Prime joined Cadence Neuroscience’s board.
Cadence develops a novel neuromodulation therapy for treating pediatric and adult patients with focal drug-resistant epilepsy. The therapy utilizes chronic subthreshold cortical stimulation. It modulates EEG biomarkers associated with epilepsy to reduce or eliminate seizures. Chu called the “precise, patient specific” stimulation method Cadence develops “unique and exciting.”
“We believe Cadence’s platform solution has the potential to become an important standard of care in drug-resistant epilepsy as well as other difficult-to-treat brain disorders,” said Paolo Di Giorgio, CEO of Angelini Ventures.
The company says it plans to use the funds raised to complete pivotal clinical studies and pursue FDA clearance.
“The Cadence team has extensive domain expertise in developing active neural implants and conducting human clinical studies in the field,” said Kent Leyde, Cadence co-founder and CEO. “During the last three years, we have been closely collaborating with Mayo Clinic in the design, manufacture, and engineering tests of our therapy system. These efforts are nearing completion and will enable us to begin clinical testing.”
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.